US Edition
Diabetic Foot and Venous Leg Ulcers Treated With BioLab’s Amnion-Based Products to Be Studied in BIOCAMP - Endovascular Today
Summary by Endovascular Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Diabetic Foot and Venous Leg Ulcers Treated With BioLab’s Amnion-Based Products to Be Studied in BIOCAMP - Endovascular Today
August 12, 2025—BioLab Holdings, Inc., recently announced the initiation of the BIOCAMP study assessing the company’s human placental membrane (HPM) products in the management of nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). The minimally manipulated allografts are derived from human amniotic membrane and designed to preserve the tissue’s natural properties and support healing, stated the company. According to BioLab, the …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
